Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...
The federal health insurance program has selected 15 additional drugs covered by Medicare Part D for its next round of price ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...
If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...
Trump could also revise what Medicare considers one drug for the ... Nordisk's branded medications with the same active ingredient – semaglutide – as one product in the second cycle of price ...
Hims & Hers’ Super Bowl ad plugs its compounded weight loss drugs as the “affordable” solution to a “sick system,” but many concerns about safety still swirl around these forms of the ...